Disparities in receipt of radiation therapy among patients with metastatic breast cancer and bone metastases: A population-based SEER analysis.
Abstract
183 Background: Radiation therapy (RT) is an important palliative modality for patients with metastatic breast cancer (MBC) and bone metastases; however, national patterns and disparities in utilization remain poorly characterized. Advances in systemic therapies may influence supportive care utilization patterns. We evaluated temporal trends, predictors of RT receipt, and survival associations using a population-based registry. Methods: We performed a retrospective SEER analysis of female patients with MBC and bone metastases diagnosed 2010–2022. Temporal trends were evaluated across three diagnosis periods. Multivariable logistic regression identified predictors of RT receipt including age, marital status, race/ethnicity, and breast cancer subtype. Overall survival was assessed using Kaplan–Meier analysis. Results: Approximately 23,400 patients were identified. Overall RT utilization was 33.5%, declining across diagnosis periods (35.4%, 33.4%, and 32.4%). RT receipt was associated with longer observed survival (median 23 vs. 16 months). Increasing age was associated with lower RT utilization. Unmarried patients had lower odds of RT receipt (OR 0.94, 95% CI 0.89–0.99, p=0.033). Non-Hispanic White patients had higher odds of RT receipt versus Hispanic patients (OR 1.10, 95% CI 1.01–1.20, p=0.028), while Non-Hispanic Black patients demonstrated a trend toward lower utilization (OR 0.90, 95% CI 0.81–1.00, p=0.057). HR−/HER2+ subtype was associated with lower RT utilization (OR 0.84, 95% CI 0.74–0.96, p=0.012). Conclusions: Significant disparities in palliative RT utilization were identified according to demographic and tumor-related factors, with RT receipt declining over time. The declining temporal trend may partly reflect evolving systemic treatment approaches, particularly among biologically selected populations including HER2-positive disease, rather than underutilization alone. These findings identify an actionable quality gap in supportive oncology delivery and highlight the need for interventions that promote equitable, goal-concordant palliative care for patients with advanced breast cancer. Radiation therapy utilization and independent predictors of lower RT receipt among patients with metastatic breast cancer and bone metastases (SEER 2010–2022). Variable Category Adjusted OR (95% CI) p-Value RT utilization 2010–2013 35.4% RT utilization 2014–2017 33.4% RT utilization 2018–2022 32.4% RT utilization Overall 33.5% Trend p<0.001 Marital Status Not married vs married 0.94 (0.89–0.99) 0.033 Race Non-Hispanic Black vs Hispanic 0.90 (0.81–1.00) 0.057 Subtype HR−/HER2+ vs HR+/HER2+ 0.84 (0.74–0.96) 0.012 Age Per decade increase 0.82 (0.81–0.84) <0.001 RT = radiation therapy; OR = odds ratio; CI = confidence interval; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2.